| Feature | Oral Wegovy | Orforglipron (Foundayo) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Status | Approved Dec 2025 | Expected June 2026 |
| Active Ingredient | Semaglutide | Orforglipron |
| Drug Type | Biologic peptide (reformulated) | Small molecule |
| Dosing | Daily, empty stomach AM, wait 30 min | Daily, any time, with or without food |
| Target | GLP-1 only | GLP-1 only |
| Weight Loss | ~15% body weight | ~14–15% body weight |
| Storage | Room temperature | Room temperature |
| Medicare Bridge | ✓ Covered | ✓ Listed (pending approval) |
The Convenience Factor Is Real
This is the single biggest practical difference. Oral Wegovy must be taken first thing in the morning on an empty stomach with exactly 4 ounces of water. No food, drinks, or other medications for 30 minutes. That's a nontrivial lifestyle constraint — especially for people who take morning medications, have unpredictable schedules, or simply want coffee before anything else.
Orforglipron eliminates all of that. Take it whenever, with or without food. This sounds minor on paper. In practice, daily medication compliance drops significantly when there are timing restrictions. Convenience isn't a luxury — it's a predictor of whether you'll actually take the medication consistently.
The Science Difference
Oral Wegovy is the same semaglutide used in the injection, reformulated with a protective coating to survive stomach acid. It's a biologic peptide — large, complex, and fragile.
Orforglipron is a small molecule — chemically simpler, easier to manufacture, and crucially, better at crossing the blood-brain barrier. A May 2026 NIH study found that small-molecule GLP-1 drugs modulate deep brain reward circuits in ways that injectable peptide drugs may not. This could mean orforglipron has a stronger effect on food cravings and hedonic eating — though more human research is needed.
The Weight Loss Numbers Are Essentially Equal
Both produce approximately 14–15% body weight loss with GLP-1-only targeting. Neither matches tirzepatide's ~22% (dual-target). The decision between these two pills should be about convenience and tolerability, not efficacy.
Switching From Injectables
The ATTAIN-MAINTAIN trial (May 2026, Nature Medicine) showed patients switching from injectable GLP-1s to orforglipron maintained 75–80% of their weight loss. Patients coming from semaglutide injections maintained weight better than those coming from tirzepatide — likely because both semaglutide and orforglipron target GLP-1 only.
Embody
Start with injectable GLP-1 for maximum initial weight loss, then discuss transitioning to an oral option with your provider when pills become available.
Compare Now →Sprout Health
Online consultation, physician-guided treatment, and medication delivered to your door. Sprout makes starting straightforward.
Compare Now →